Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -0.74%67 1-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates BSP:OFSA3 with a GF Score™ of 67/100 and a GF Value™ of R$26.51 (Fairly Valued). The stock has 3 warning signs investors should review. Among 496 Drug Manufacturers companies, Ourofino ranks worse than 201612.7% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Ourofino's current 1-Year Share Buyback Ratio was 0.00%.
BSP:OFSA3's 1-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -2 * Ranked among companies with meaningful 1-Year Share Buyback Ratio only.
Ourofino (BSP:OFSA3) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Ourofino 1-Year Share Buyback Ratio Related Terms
BSP:OFSA3 vs ZTS, UTHR, VTRS: 1-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino 1-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Ourofino's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of 0.00 mean?
Ourofino (BSP:OFSA3) has a 1-Year Share Buyback Ratio of 0.00 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Ourofino and its competitors. According to the industry distribution chart, Ourofino ranks #999999 out of 496 companies in the Drug Manufacturers industry.
Is Ourofino's 1-Year Share Buyback Ratio too high?
Ourofino's current 1-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Ourofino ranks #999999 out of 496 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ourofino has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's 1-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #999999 out of 496 companies for 1-Year Share Buyback Ratio. This places Ourofino in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 1-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Ourofino and its competitors. Ourofino's current 1-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.51, compared to a current price of R$27.00 — trading 1.8% above its estimated fair value. The current 1-Year Share Buyback Ratio is 0.00. Ourofino's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current 1-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be overvalued.
The current stock price of R$27.00 is trading 1.8% above its estimated GF Value™ of R$26.51.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
1-Year Share Buyback Ratio: 0.00
GF Value™: R$26.51 vs. price of R$27.00 (1.8% above fair value)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
67GF Score
Get the complete analysis for BSP:OFSA3
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
